Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities
Because of its high infectivity in humans and the lack of effective vaccines, Nipah virus is classified as a category C agent and handling has to be performed under biosafety level 4 conditions in non-endemic countries, which has hindered the development of vaccines. Based on a highly efficient pseu...
Saved in:
| Main Authors: | Jianhui Nie, Lin Liu, Qing Wang, Ruifeng Chen, Tingting Ning, Qiang Liu, Weijin Huang, Youchun Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2019.1571871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HIV-1 pseudoviruses constructed in China regulatory laboratory
by: Jianhui Nie, et al.
Published: (2020-01-01) -
Development and Validation of a Standardized Pseudotyped Virus-Based Neutralization Assay for Assessment of Anti-Nipah Virus Neutralizing Activity in Candidate Nipah Vaccines
by: Muntasir Alam, et al.
Published: (2025-07-01) -
Novel transcription and replication-competent virus-like particles system modelling the Nipah virus life cycle
by: Yulong Wang, et al.
Published: (2024-12-01) -
Cross-protectivity of henipavirus soluble glycoprotein in an in vivo model of Nipah virus disease
by: Stephen Findlay-Wilson, et al.
Published: (2025-02-01) -
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
by: Jianhui Nie, et al.
Published: (2020-01-01)